AXL – a new player in resistance to HER2 blockade

Cancer; HER2 disease; Resistance

Bibliographic Details
Authors: Cejalvo, Juan Miguel, ADAM-ARTIGUES, ANNA, ARENAS LAHUERTA, ENRIQUE JAVIER, Arribas, Joaquin, Prat, Aleix
Format: article
Status:Published version
Publication Date:2023
Country:España
Institution:Departament de Salut de la Generalitat de Catalunya (DS)
Repository:Scientia. Dipòsit d'Informació Digital del Departament de Salut
OAI Identifier:oai:scientiasalut.gencat.cat:11351/10567
Online Access:https://hdl.handle.net/11351/10567
Access Level:Open access
Keyword:Càncer - Tractament
Resistència als medicaments
DISEASES::Neoplasms
Other subheadings::Other subheadings::Other subheadings::/drug therapy
PHENOMENA AND PROCESSES::Physiological Phenomena::Pharmacological and Toxicological Phenomena::Pharmacological Phenomena::Drug Resistance::Drug Resistance, Neoplasm
ENFERMEDADES::neoplasias
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
FENÓMENOS Y PROCESOS::fenómenos fisiológicos::fenómenos farmacológicos y toxicológicos::fenómenos farmacológicos::resistencia a medicamentos::resistencia a los antineoplásicos
id ES_ef07cdc012efc2ff8881bb2553367e28
oai_identifier_str oai:scientiasalut.gencat.cat:11351/10567
network_acronym_str ES
network_name_str España
repository_id_str
spelling AXL – a new player in resistance to HER2 blockadeCejalvo, Juan MiguelADAM-ARTIGUES, ANNAARENAS LAHUERTA, ENRIQUE JAVIERArribas, JoaquinPrat, AleixCàncer - TractamentResistència als medicamentsDISEASES::NeoplasmsOther subheadings::Other subheadings::Other subheadings::/drug therapyPHENOMENA AND PROCESSES::Physiological Phenomena::Pharmacological and Toxicological Phenomena::Pharmacological Phenomena::Drug Resistance::Drug Resistance, NeoplasmENFERMEDADES::neoplasiasOtros calificadores::Otros calificadores::Otros calificadores::/farmacoterapiaFENÓMENOS Y PROCESOS::fenómenos fisiológicos::fenómenos farmacológicos y toxicológicos::fenómenos farmacológicos::resistencia a medicamentos::resistencia a los antineoplásicosCancer; HER2 disease; ResistanceCàncer; Malaltia HER2; ResistènciaCáncer; Enfermedad HER2; ResistenciaHER2 is a driver in solid tumors, mainly breast, oesophageal and gastric cancer, through activation of oncogenic signaling pathways such as PI3K or MAPK. HER2 overexpression associates with aggressive disease and poor prognosis. Despite targeted anti-HER2 therapy has improved outcomes and is the current standard of care, resistance emerge in some patients, requiring additional therapeutic strategies. Several mechanisms, including the upregulation of receptors tyrosine kinases such as AXL, are involved in resistance. AXL signaling leads to cancer cell proliferation, survival, migration, invasion and angiogenesis and correlates with poor prognosis. In addition, AXL overexpression accompanied by a mesenchymal phenotype result in resistance to chemotherapy and targeted therapies. Preclinical studies show that AXL drives anti-HER2 resistance and metastasis through dimerization with HER2 and activation of downstream pathways in breast cancer. Moreover, AXL inhibition restores response to HER2 blockade in vitro and in vivo. Limited data in gastric and oesophageal cancer also support these evidences. Furthermore, AXL shows a strong value as a prognostic and predictive biomarker in HER2+ breast cancer patients, adding a remarkable translational relevance. Therefore, current studies enforce the potential of co-targeting AXL and HER2 to overcome resistance and supports the use of AXL inhibitors in the clinic.ElsevierInstitut Català de la Salut[Adam-Artigues A] INCLIVA Biomedical Research Institute, València, Spain. [Arenas EJ] Josep Carreras Leukaemia Research Institute, Barcelona, Spain. Center for Biomedical Network Research on Cancer (CIBERONC), Barcelona, Spain. [Arribas J] Center for Biomedical Network Research on Cancer (CIBERONC), Barcelona, Spain. Preclinical Research Program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), Barcelona Spain. Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Bellaterra, Spain. Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain. [Prat A] August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. Department of Medical Oncology, Hospital Clínic de Barcelona, Barcelona, Spain. SOLTI Breast Cancer Research Group, Barcelona, Spain. [Cejalvo JM] INCLIVA Biomedical Research Institute, València, Spain. Preclinical Research Program, Vall d’Hebron Institute of Oncology (VHIO), Biblioteca, Spain. Department of Medical Oncology, Hospital Clínico Universitario de València, València, SpainVall d'Hebron Barcelona Hospital Campus202320232023info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/11351/10567Scientiareponame:Scientia. Dipòsit d'Informació Digital del Departament de Salutinstname:Departament de Salut de la Generalitat de Catalunya (DS)InglésCancer Treatment Reviews;121https://doi.org/10.1016/j.ctrv.2023.102639Attribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:scientiasalut.gencat.cat:11351/105672026-06-12T09:38:37Z
dc.title.none.fl_str_mv AXL – a new player in resistance to HER2 blockade
title AXL – a new player in resistance to HER2 blockade
spellingShingle AXL – a new player in resistance to HER2 blockade
Cejalvo, Juan Miguel
Càncer - Tractament
Resistència als medicaments
DISEASES::Neoplasms
Other subheadings::Other subheadings::Other subheadings::/drug therapy
PHENOMENA AND PROCESSES::Physiological Phenomena::Pharmacological and Toxicological Phenomena::Pharmacological Phenomena::Drug Resistance::Drug Resistance, Neoplasm
ENFERMEDADES::neoplasias
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
FENÓMENOS Y PROCESOS::fenómenos fisiológicos::fenómenos farmacológicos y toxicológicos::fenómenos farmacológicos::resistencia a medicamentos::resistencia a los antineoplásicos
title_short AXL – a new player in resistance to HER2 blockade
title_full AXL – a new player in resistance to HER2 blockade
title_fullStr AXL – a new player in resistance to HER2 blockade
title_full_unstemmed AXL – a new player in resistance to HER2 blockade
title_sort AXL – a new player in resistance to HER2 blockade
dc.creator.none.fl_str_mv Cejalvo, Juan Miguel
ADAM-ARTIGUES, ANNA
ARENAS LAHUERTA, ENRIQUE JAVIER
Arribas, Joaquin
Prat, Aleix
author Cejalvo, Juan Miguel
author_facet Cejalvo, Juan Miguel
ADAM-ARTIGUES, ANNA
ARENAS LAHUERTA, ENRIQUE JAVIER
Arribas, Joaquin
Prat, Aleix
author_role author
author2 ADAM-ARTIGUES, ANNA
ARENAS LAHUERTA, ENRIQUE JAVIER
Arribas, Joaquin
Prat, Aleix
author2_role author
author
author
author
dc.contributor.none.fl_str_mv Institut Català de la Salut
[Adam-Artigues A] INCLIVA Biomedical Research Institute, València, Spain. [Arenas EJ] Josep Carreras Leukaemia Research Institute, Barcelona, Spain. Center for Biomedical Network Research on Cancer (CIBERONC), Barcelona, Spain. [Arribas J] Center for Biomedical Network Research on Cancer (CIBERONC), Barcelona, Spain. Preclinical Research Program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), Barcelona Spain. Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Bellaterra, Spain. Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain. [Prat A] August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. Department of Medical Oncology, Hospital Clínic de Barcelona, Barcelona, Spain. SOLTI Breast Cancer Research Group, Barcelona, Spain. [Cejalvo JM] INCLIVA Biomedical Research Institute, València, Spain. Preclinical Research Program, Vall d’Hebron Institute of Oncology (VHIO), Biblioteca, Spain. Department of Medical Oncology, Hospital Clínico Universitario de València, València, Spain
Vall d'Hebron Barcelona Hospital Campus
dc.subject.none.fl_str_mv Càncer - Tractament
Resistència als medicaments
DISEASES::Neoplasms
Other subheadings::Other subheadings::Other subheadings::/drug therapy
PHENOMENA AND PROCESSES::Physiological Phenomena::Pharmacological and Toxicological Phenomena::Pharmacological Phenomena::Drug Resistance::Drug Resistance, Neoplasm
ENFERMEDADES::neoplasias
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
FENÓMENOS Y PROCESOS::fenómenos fisiológicos::fenómenos farmacológicos y toxicológicos::fenómenos farmacológicos::resistencia a medicamentos::resistencia a los antineoplásicos
topic Càncer - Tractament
Resistència als medicaments
DISEASES::Neoplasms
Other subheadings::Other subheadings::Other subheadings::/drug therapy
PHENOMENA AND PROCESSES::Physiological Phenomena::Pharmacological and Toxicological Phenomena::Pharmacological Phenomena::Drug Resistance::Drug Resistance, Neoplasm
ENFERMEDADES::neoplasias
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
FENÓMENOS Y PROCESOS::fenómenos fisiológicos::fenómenos farmacológicos y toxicológicos::fenómenos farmacológicos::resistencia a medicamentos::resistencia a los antineoplásicos
description Cancer; HER2 disease; Resistance
publishDate 2023
dc.date.none.fl_str_mv 2023
2023
2023
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/11351/10567
url https://hdl.handle.net/11351/10567
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Cancer Treatment Reviews;121
https://doi.org/10.1016/j.ctrv.2023.102639
dc.rights.none.fl_str_mv Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv Scientia
reponame:Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname:Departament de Salut de la Generalitat de Catalunya (DS)
instname_str Departament de Salut de la Generalitat de Catalunya (DS)
reponame_str Scientia. Dipòsit d'Informació Digital del Departament de Salut
collection Scientia. Dipòsit d'Informació Digital del Departament de Salut
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869423825411637248
score 15,81155

Similar Items